ZILOSUL – 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測

Report Overview

KEY INSIGHTS

ZILOSUL, also known as pentosan polysulfate sodium (PPS), is a semi-synthetic medication derived from the wood chips of European beech trees. The extraction process yields glucurono-xylans, which are then sulfated to create a negatively charged substance that resembles glycosaminoglycans (GAGs). GAGs are complex carbohydrates that interact with proteins involved in inflammatory processes, thereby regulating various bodily functions.

PPS is known for its anti-inflammatory and tissue regenerative properties, along with a mild anti-thrombotic effect. Given its multiple mechanisms of action, Paradigm is investigating the potential of PPS to treat a range of conditions that originate from and are maintained by inflammation, such as osteoarthritis. This approach is particularly relevant given the increased prevalence of osteoarthritis and the demand for effective osteoarthritis treatments.

The drug is developed by Paradigm Biopharmaceuticals Limited, an Australian biopharmaceutical company dedicated to developing innovative therapies aimed at addressing unmet medical needs. The company’s focus is on the late-stage development of treatments derived from pentosan polysulfate sodium (PPS), a semi-synthetic compound with potential applications in a wide range of diseases. Paradigm’s current research pipeline includes the development of PPS-based therapies targeting inflammatory conditions, particularly respiratory disorders such as allergic rhinitis, allergic asthma, and chronic obstructive pulmonary disease.

MARKET POTENTIAL AND POSITIONING

ZILOSUL is a semi-synthetic drug formulated with pentosan polysulfate sodium (PPS), sourced from xylans of European beech trees. It is specifically designed to treat osteoarthritis by targeting the underlying disease mechanisms rather than simply alleviating symptoms. ZILOSUL supports the health of cartilage and joint tissues, which may lead to enhanced joint function and reduced pain for patients.

Administered through subcutaneous injection, the drug is currently in Phase III clinical trials to determine its efficacy and safety in individuals with osteoarthritis. Its distinctive mechanism of action presents ZILOSUL as a promising new treatment option in the evolving field of osteoarthritis management.

In March 2023, Paradigm Biopharmaceuticals announced it had obtained parallel regulatory and ethics approvals for the pivotal PARA_OA_002 clinical trial across Belgium, Poland, and the Czech Republic. The Phase III PARA_OA_002 trial is a randomized, double-blind, placebo-controlled, multicenter study (spanning the US, Australia, the UK, the EU, and Canada) designed to assess the dosage and therapeutic effect of injectable pentosan polysulfate sodium (iPPS) in participants suffering from knee osteoarthritis pain. The application for the PARA_OA_002 trial was submitted through Europe’s newly established Clinical Trials Information System (CTIS) for evaluation in three European nations.

REGIONAL ANALYSIS

Inkwood Research offers an analysis of seven key markets:

• United States
• Germany
• France
• United Kingdom

o The UK Government has allocated approximately £69 million (~ $86 million) for research into musculoskeletal (MSK) conditions, including osteoarthritis. However, this amount is considered insufficient to adequately address the growing needs of patients suffering from these debilitating conditions.

o Organizations like Versus Arthritis have called on the government to increase funding for MSK research to develop more effective treatments and interventions. They argue that more substantial investment is necessary to keep pace with the rising prevalence of osteoarthritis and other related disorders, improve patient outcomes, and reduce the long-term healthcare costs associated with these conditions.

o Moreover, the UK’s healthcare system, the NHS, is focusing on improving patient access to cutting-edge treatments and rehabilitation programs. This holistic approach, supported by ongoing investments, aims to reduce the overall burden of osteoarthritis on the healthcare system, improve patient outcomes, and enhance the quality of life for those affected.

• Italy
• Spain
• Japan

Table of Contents

1. INTRODUCTION TO THE REPORT
2. ZILOSUL OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. ZILOSUL MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF ZILOSUL IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF ZILOSUL IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF ZILOSUL IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF ZILOSUL IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF ZILOSUL IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF ZILOSUL IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF ZILOSUL IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF ZILOSUL IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF ZILOSUL IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: ZILOSUL, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: ZILOSUL, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: ZILOSUL MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: ZILOSUL MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: ZILOSUL MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: ZILOSUL MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: ZILOSUL MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: ZILOSUL MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: ZILOSUL MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: ZILOSUL MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: ZILOSUL MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: ZILOSUL MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: ZILOSUL MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: ZILOSUL MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: ZILOSUL MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: ZILOSUL MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: ZILOSUL MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: ZILOSUL MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧